Home  >  Partners
Tetra Bio-Pharma’s Development Partners below. Tetra is seeking commercialization partnerships for all our products listed under Phyto Pain.

Algorythm Pharma is conducting stage 1 clinical trials of PP001 in collaboration with Phyto Pain Pharma


Mcgill Univeristy is collaborating with Agro tek and Grow Pros on an NSERC funded reaserch study to develop consumer products containing cannabanoids.


Aphria is a publically traded producer of medical Cannabis under license from the Canadian Federal Government. Aphria has partnered with PPP for the production of Cannabis for use in PP001


The National Sciences and Engineering Research Council of Canada connects industry with world-firsts in knowledge and the people behind them, fuelling R&D and leading to firsts in the marketplace. They have granted TBP subsidiary Grow Pros Cannabis with research funding related to the development of Consumer products in collaboration with the university of McGill.


Tetra Bio-Pharma and The New Brunswick Health Research Foundation are investing a combined $1 million, $500,000 each over five years to establish a Health Research Chair in Cannabis at the University of New Brunswick (UNB). The chair will focus on the study of biochemistry, medicinal use and pharmacology of cannabis. This research will expand UNB’s commitment to research and innovation in the field of natural product and biomedical, health and life sciences – adding to its reputation as a leader in natural products’ research.


Tetra Bio-Pharma and IntelGenx Corp. have a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol XL - PPP002 for the management of anorexia and cancer chemotherapy-related pain.


Tetra Bio-Pharma and Panag Pharma have a definitive agreement for two products, PPP003 and PPP004 for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion.